15 Posts From ASCO24 Day 2 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May 31st to June 4th 2024.
Our team at OncoDaily selected the most important posts from Day 2 of ASCO24 that you should not miss.
To ALL those we have lost to cancer…and to our survivors as well, in your honor, we will continue to fight cancer and comfort those who suffer from it…all over the world.
Today, ECO President Csaba Dégi met with Arman Kacharian, Head of the Innovations Expert Group at the Ministry of Health of Ukraine.
Ukrainian cancer specialists at the ASCO Congress shared how their Workforce and Patient care needs can be supported by international colleagues.
ECO and ASCO’s long-term commitment to supporting cancer professionals and patients in Ukraine remains intact. Read our ECO report on Cancer Medicines Shortages During the War in Ukraine.
Excited to present my poster this morning at the American Society of Clinical Oncology (ASCO24) annual meeting and about an important area of research on brain cancer (MDM4-amplified high-grade glioma) that needs much more worldwide attention.
- June 1, 2024
- Poster session 9:00 am-Noon
- Hall A
- Central Nervous System Tumors
- Abstract 2080
- Poster Board 379
Therapeutic insights for the aggressive subset of High-Grade Gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT.
Our work at Brown and Legorreta Cancer Centers was conducted in collaboration with Caris Life Sciences.
In Oncology/Neuro-Oncology there is a significant unmet need in GBM with MDM4 amplification. These MDM4-amplified GBM’s:
- Represent 5-10% of GBMs,
- Involve MDM4 as a potent driver (blocks p53 pathway, suppresses T-cell killing, is co-amplified with other targetable drivers),
- There are no FDA-approved drugs in 2024 or any being tested against the target (either MDM4-specific or dual MDM2-MDM4) in GBM.
MDM4 is associated with worse outcomes regardless of MGMT methylation status, and I previously presented worse outcomes across tumor types (El-Deiry et al., ASCO, 2022) including after immune checkpoint blockade.
We now recognize genetically linked targetable associated amplified genes that are overexpressed, coming from the same amplicon. These include kinase PIK3C2B and phosphatase PPP1R15B, among others. There are opportunities for combinations with other agents active in GBM.
I would be very happy to collaborate with anyone interested in supporting progress on this deadly disease where our insights suggest novel therapy strategies to help patients with aggressive MDM4-amplified GBMs.
LBA out: Phase 3 EVOKE-01 study. Sacituzumab vs Docetaxel… and… no better! Underwhelming results.
One subgroup to note ‘Clinically meaningful improvement of OS was noted in patients without response to prior IO’. 383 patients OS 8.3 vs 11.8 for these patients HR 0.75 (0.58–0.97).
Can we talk about this truly phenomenal group of trainees, each with an ASCO24 poster and/or oral presentation?
Their work highlights important equity gaps in vulnerable populations. Their passion about improving cancer care is clear. The future of oncology is bright.
I’m honored and humbled to receive the distinction of FASCO (Fellow of the American Society of Clinical Oncology) at ASCO24.
It’s been an honoring and fulfilling experience to serve and contribute to the GREAT mission of a GREAT society along with GREAT staff and colleagues.
Found the most wanted dog at ASCO24. Otto is being trained to detect early cancer.
PS: it is ok to pet Otto.
We constructed an immune cell state atlas that allows us to resolve complex immune architectures within the TME.
They are made with distinct immune cell types and cell states in an effort to refine the process of patient selection for immunotherapy and gain insights into immune-resistance mechanisms that guide future immunotherapy drug development.
The Conquer Cancer, the ASCO Foundation’s Grants and Awards ceremony is my favorite event at ASCO Annual Meetings every year.
This year, I was proud to see 3 Nepali colleagues get on the stage to receive different awards at ASCO24! The future of oncology in Nepal is bright.
ASCO24 Lung Rapid Orals
Phase II trial Amivantamab/lazertinib in patients with brain metastasis (BM) and Leptomeningeal diagnosis (LMD) in EGFR+ nsclc: – 40% CNS RR in BM – 33% ORR in LMD, treatment duration 8 months.
Bravo, Helena Yu. A major area of need in EGFR+ disease.
This has to be a Best of ASCO24 moment. Running alongside GI oncology legend at Shaalan Beg has been a dream come true at the Inaugural 5K this morning. I had to add a few miles back to the hotel to prove I was worth my salt.
Sending a big thank you to the ASCO advocacy team (partially represented here). We are so grateful for all of the work you do on behalf of our patients, their caregivers, and oncology professionals.
This session happened because of you!
Thrilled with the launch of our ASCO Cancer Survivorship COP! Fantastic discussion with panelists including the one who led us here, Dr. Patti Ganz! The amazing Drs. Melissa Hudson and Lidia Schapira!
Our newer and future leaders! And of course, Nicole Stout at ASCO24.
ASCO president Lynn Schuchter emphasizes how important communication is in oncology care at ASCO24.
We focus so much on the technical and scientific aspects of delivering care, but our communication skills often aren’t given the same attention and development.
NRG-LU002: maintenance systemic therapy vs local consolidative therapy plus maintenance therapy in oligometastatic NSCLC.
90% having received IO-based therapy. Adding LCT does not improve survival. It increases side effects. Presented by Dr. Puneeth Iyengar.
